학술논문

Evolution of cefiderocol resistance in Stenotrophomonas maltophilia using in vitro serial passage techniques
Document Type
Academic Journal
Source
JAC-Antimicrobial Resistance. February 2022, Vol. 4 Issue 1
Subject
Physiological aspects
Analysis
Methods
Penicillins -- Physiological aspects -- Analysis -- Methods
Avibactam -- Physiological aspects -- Analysis -- Methods
Demeclocycline -- Methods -- Physiological aspects -- Analysis
Cephalosporins -- Physiological aspects -- Analysis -- Methods
Genomes -- Physiological aspects -- Methods -- Analysis
Genomics -- Physiological aspects -- Methods -- Analysis
Sulfonamides -- Analysis -- Physiological aspects -- Methods
Moxalactam -- Physiological aspects -- Analysis -- Methods
Penicillin -- Physiological aspects -- Analysis -- Methods
Cephaloridine -- Physiological aspects -- Analysis -- Methods
Language
English
Abstract
Introduction Cefiderocol is a siderophore cephalosporin with activity against Gram-negatives including many carbapenem-resistant strains, although most isolates included in studies have been Enterobacterales or P. aeruginosa. (1,2) There is limited [...]
Objectives: Cefiderocol is a siderophore cephalosporin active against MDR Gram- negatives including Stenotrophomonas maltophilia. Cefiderocol resistance remains uncommon and incompletely understood. We selected for cefiderocol-resistant S. maltophilia in vitro and characterized the genetic mechanisms and potential for cross-resistance to other antimicrobials. Methods: We selected cefiderocol resistance in three clinical strains of S. maltophilia by serial passage in escalating concentrations of cefiderocol. Emergent cefiderocol-resistant isolates were subjected to repeat susceptibility testing against a panel of relevant antimicrobials. Isolates with confirmed MIC changes were whole genome sequenced. Results: Each parent strain was initially susceptible to cefiderocol (MICs of 0.03125, 0.03125 and 0.125 mg/L), and one initially tested susceptible to ceftazidime/avibactam (MIC 4 mg/L). We recovered evolved isolates achieving cefiderocol resistance at MICs of 8-32 mg/L from each parental strain. Some cefiderocol resistant isolates reverted following one to four drug-free passages. Ceftazidime/avibactam MICs of passaged isolates repeatedly increased to [greater than or equal to] 256 mg/L, and while other MICs were largely unchanged, trimethoprim/sulfamethoxazole MICs declined 4-fold in two strains. WGS revealed one evolved isolate carrying six coding mutations, while four were isogenic mutants of tonB, tolQ, smf-1 and the smeT promoter. Mutation of the smeT promoter downregulated the smeDEF efflux pump and reduced susceptibility to penicillins but increased susceptibility to several other classes including sulphonamides. Other mutations occurred in genes putatively involved in iron metabolism including smlt1148 and cirA. Conclusions: S. maltophilia strains evolved cefiderocol resistance through different genetic pathways, but often involved iron transport. Future work is required to fully understand the role(s) of other genes in cefiderocol resistance.